Table 1. Baseline characteristics.
| Baseline characteristics | US cohort | Finnish cohorta | ||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Male (N = 502) | Female (N = 597) | p value | Male (N = 22,961) | Female (N = 44,088) | p value | |
| Age at diagnosis (years) | 0.175 | <0.001 | ||||
| Mean (SD) | 79.8 (6.64) | 80.4 (8.02) | 79.5 (6.0) | 81.2 (6.1) | ||
| Minimum, maximum | 65, 98 | 65, 104 | 65, 101 | 65, 103 | ||
| Co-morbidities, N (%) | ||||||
| Cardiovascular disease | 382 (76.1) | 411 (68.8) | 0.008 | 12,481 (54.4; 53.7–55.0) | 22,601 (51.3; 50.1–51.7) | <0.001 |
| Stroke | 34 (6.8) | 38 (6.4) | 0.786 | 3050 (13.3; 12.9–13.7) | 3958 (9.0; 8.7–9.3) | <0.001 |
| Seizures (US cohort)/epilepsy (Finnish cohort) | 11 (2.2) | 13 (2.2) | 0.988 | 603 (2.6; 2.4–2.8) | 809 (1.8; 1.7–2.0) | <0.001 |
| Diabetes mellitus | 74 (14.7) | 62 (10.4) | 0.029 | 3764 (16.4; 15.9–16.9) | 5536 (12.6; 12.3–12.9) | <0.001 |
| Number of medications, N (%) | 0.128 | <0.001 | ||||
| Mean (SD) | 7 (3.59) | 6.6 (3.79) | 5.5 (3.3) | 5.8 (3.4) | ||
| Minimum, maximum | 0, 20 | 0, 21 | 0, 23 | 0, 23 | ||
| Number of medication categories, N (%) | 0.008 | <0.001 | ||||
| 0 | 9 (1.8) | 18 (3.1) | 835 (3.6; 3.4–3.9) | 1354 (3.1; 2.9–3.2) | ||
| 1–4 | 110 (22.4) | 175 (29.8) | 8809 (38.4; 37.7–39.0) | 15,759 (35.7; 35.3–36.2) | ||
| 5–9 | 269 (54.7) | 267 (45.5) | 10,493 (45.7; 45.1–46.3) | 20,872 (47.3; 46.9–47.8) | ||
| 10 and more | 104 (21.1) | 127 (21.6) | 2824 (12.3; 11.9–12.7) | 6103 (13.8; 13.5–14.2) | ||
| Cognitive enhancers, N (%) | ||||||
| Any approved drugs for AD treatment | 324 (64.5) | 312 (52.3) | <0.001 | 15,973 (69.6; 69.0–70.2) | 29,425 (66.7; 66.3–67.2) | <0.001 |
| Memantine | 151 (30.1) | 131 (21.9) | 0.007 | 3280 (14.3; 13.8–14.7) | 5777 (13.1; 12.8–13.4) | <0.001 |
| Cholinesterase inhibitors | 297 (59.2) | 288 (48.2) | <0.001 | 13,341 (58.1; 57.5–58.7) | 24,850 (56.4; 55.9–56.8) | <0.001 |
AD Alzheimer's disease, CI confidence interval, SD standard deviation
a
For the Finnish cohort, table includes N (%) with 95% CI for %